Search

everythinglearnresearchcommunity

for

Search:↓

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

The gene therapy showed significant wound healing and was safe for treating severe RDEB.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ixekizumab has known and some unexpected side effects.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Entospletinib effectively prevents eye and skin GVHD in mice.

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

A new therapy for a skin blistering condition has not been developed yet.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

The specific skin disease variant p.(Arg2000Trp) in plectin can cause a wide range of symptoms, which should be considered when diagnosing patients.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.

Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.

A new method improves betulin delivery in experiments, showing promise against certain tumors.

Natural gene therapy shows promise for treating skin disorders like epidermolysis bullosa.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.